JP2022537384A5 - - Google Patents

Info

Publication number
JP2022537384A5
JP2022537384A5 JP2021575509A JP2021575509A JP2022537384A5 JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5 JP 2021575509 A JP2021575509 A JP 2021575509A JP 2021575509 A JP2021575509 A JP 2021575509A JP 2022537384 A5 JP2022537384 A5 JP 2022537384A5
Authority
JP
Japan
Prior art keywords
approximately
azacitidine
days
pharmaceutical composition
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038760 external-priority patent/WO2020257665A1/en
Publication of JP2022537384A publication Critical patent/JP2022537384A/ja
Publication of JP2022537384A5 publication Critical patent/JP2022537384A5/ja
Pending legal-status Critical Current

Links

JP2021575509A 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン Pending JP2022537384A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962864413P 2019-06-20 2019-06-20
US62/864,413 2019-06-20
PCT/US2020/038760 WO2020257665A1 (en) 2019-06-20 2020-06-19 Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
JP2022537384A JP2022537384A (ja) 2022-08-25
JP2022537384A5 true JP2022537384A5 (cg-RX-API-DMAC10.html) 2023-06-08

Family

ID=71528047

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021575387A Pending JP2022537551A (ja) 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン
JP2021575509A Pending JP2022537384A (ja) 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021575387A Pending JP2022537551A (ja) 2019-06-20 2020-06-19 ベネトクラクス、ギルテリチニブ、ミドスタウリン、または白血病もしくは骨髄異形成症候群を治療するための他の化合物との組み合わせにおけるアザシチジン

Country Status (11)

Country Link
US (2) US12447171B2 (cg-RX-API-DMAC10.html)
EP (2) EP3986404A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022537551A (cg-RX-API-DMAC10.html)
KR (2) KR20220050874A (cg-RX-API-DMAC10.html)
CN (2) CN115066243A (cg-RX-API-DMAC10.html)
AU (2) AU2020297596A1 (cg-RX-API-DMAC10.html)
BR (2) BR112021025537A2 (cg-RX-API-DMAC10.html)
CA (2) CA3143711A1 (cg-RX-API-DMAC10.html)
IL (2) IL289115A (cg-RX-API-DMAC10.html)
MX (2) MX2021015993A (cg-RX-API-DMAC10.html)
WO (2) WO2020257671A1 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2841572B1 (en) 2012-04-27 2019-06-19 Duke University Genetic correction of mutated genes
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
US10676726B2 (en) 2015-02-09 2020-06-09 Duke University Compositions and methods for epigenome editing
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
US12214054B2 (en) 2015-11-30 2025-02-04 Duke University Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
EP3443081A4 (en) 2016-04-13 2019-10-30 Duke University CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE
JP7490211B2 (ja) 2016-07-19 2024-05-27 デューク ユニバーシティ Cpf1に基づくゲノム編集の治療適用
US12509492B2 (en) 2018-01-19 2025-12-30 Duke University Genome engineering with CRISPR-Cas systems in eukaryotes
TWI887234B (zh) 2019-04-14 2025-06-21 美國公爵大學 治療杜興氏(duchenne)肌肉失養症之大型突變熱點之aav載體介導之刪除
WO2022187288A2 (en) * 2021-03-01 2022-09-09 Duke University Systems and methods for genome-wide annotation of gene regulatory elements linked to cell fitness
JP7898763B2 (ja) * 2021-04-05 2026-08-03 ピノットバイオ インコーポレイテッド 4’-チオ-5-アザ-2’-デオキシシチジンおよびベネトクラクスの併用療法
WO2022240788A1 (en) * 2021-05-11 2022-11-17 Abbvie Inc. Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine
BR112023023677A2 (pt) * 2021-05-11 2024-02-20 Abbvie Inc Regimes de dosagem de venetoclax para o uso no tratamento de síndromes mielodisplásicas em combinação com azacitidina
US20250312327A1 (en) * 2021-10-14 2025-10-09 Pharos Ibio Co., Ltd Composition for combination therapy, comprising 2,3,5-substituted thiophene compound
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CA3260237A1 (en) 2022-06-24 2023-12-28 Tune Therapeutics, Inc. Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3782612T3 (da) 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
WO2015168466A1 (en) 2014-05-01 2015-11-05 Quanticel Pharmaceuticals, Inc. Inhibitors of lysine specific demethylase-1
ES2935114T3 (es) 2014-09-05 2023-03-01 Celgene Quanticel Res Inc Inhibidores de la desmetilasa 1 específica de lisina
EA201790543A1 (ru) 2014-09-08 2017-07-31 Селджин Корпорейшн Способы лечения заболевания или расстройства с использованием составов для перорального применения, содержащих аналоги цитидина, в комбинации с моноклональным антителом к pd1 или pdl1
CA3002029A1 (en) 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
MX373363B (es) 2015-11-05 2020-05-21 Celgene Quanticel Res Inc Composiciones que comprenden un inhibidor de demetilasa-1 específico de lisina.
SG10201913290QA (en) * 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
WO2018106984A1 (en) * 2016-12-09 2018-06-14 Constellation Pharmaceuticals, Inc. Markers for personalized cancer treatment with lsd1 inhibitors
EP4201399A3 (en) 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療

Similar Documents

Publication Publication Date Title
JP2023041862A5 (cg-RX-API-DMAC10.html)
US6346519B1 (en) Method and composition for treating arthritis
JP2024109585A5 (cg-RX-API-DMAC10.html)
JP2023088944A5 (cg-RX-API-DMAC10.html)
JP2023503309A5 (cg-RX-API-DMAC10.html)
JP2022537551A5 (cg-RX-API-DMAC10.html)
JP2020503269A5 (cg-RX-API-DMAC10.html)
JP2018507243A5 (cg-RX-API-DMAC10.html)
JP2006516571A5 (cg-RX-API-DMAC10.html)
JP2020500864A5 (cg-RX-API-DMAC10.html)
TW200402301A (en) Treatment of mucositis
Huynh et al. Current concepts in acute pain management
CN111902137A (zh) 增强5-羟色氨酸的生物利用度的组合物和方法
Theofilis et al. The role of melatonin in chronic kidney disease and its associated risk factors: a new tool in our arsenal?
JP2016505050A5 (cg-RX-API-DMAC10.html)
JP2022511126A (ja) R-chopとの組み合わせ及び複合薬におけるチダミドの適用
BR112023000598A2 (pt) Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia
JP2022553888A5 (cg-RX-API-DMAC10.html)
JP2024531799A5 (cg-RX-API-DMAC10.html)
JP2025511402A5 (cg-RX-API-DMAC10.html)
WO2010023874A1 (ja) ロペラミド塩酸塩含有フィルム製剤
JP2024540439A5 (cg-RX-API-DMAC10.html)
JP2021517128A5 (cg-RX-API-DMAC10.html)
Motamedi et al. Use of pure nicotine for the treatment of aphthous ulcers
CN104936585B (zh) 包括苯肾上腺素和扑热息痛的组合药剂